Absci Corp (ABSI)

Currency in USD
9.180
-0.280(-2.96%)
Closed·
9.200+0.020(+0.22%)
·
ABSI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.8309.435
52 wk Range
2.24012.055
Key Statistics
Prev. Close
9.18
Open
9.43
Day's Range
8.83-9.435
52 wk Range
2.24-12.055
Volume
2.23M
Average Volume (3m)
5.08M
1-Year Change
213.3106%
Book Value / Share
1.45
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABSI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.889
Upside
+51.30%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

Absci Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Strong Buy

Analyst Ratings

9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.889
(+51.30% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Truist Securities
Buy17.00+85.19%11.00Maintain02-07-2026
Morgan Stanley
Hold10.00+8.93%4.10Maintain25-06-2026
H.C. Wainwright
Buy16.00+74.29%8.00Maintain25-06-2026
Jones Trading
Buy13.00+41.61%11.00Maintain24-06-2026
Guggenheim
Buy15.00+63.40%10.00Maintain15-06-2026

Absci Corp Earnings Call Summary for Q2/2026

  • Absci posted Q2 loss of $0.21/share vs. $0.19 expected; revenue of $300K missed $1.01M forecast by 70.3%, sending shares down 17.43% after-hours.
  • Cash position rose to $201.1M from $125.7M, bolstered by $93.6M stock offering and $40M Eli Lilly investment; runway extended into H2 2028.
  • Lead candidate ABS-201 showed favorable interim safety data; 13-week HEADLINE trial results expected H2 2026, full 26-week data due early 2027.
  • Phase II endometriosis trial planned for Q4 2026 with proof-of-concept data anticipated H2 2027; management estimates $25B+ U.S. market opportunity.
  • R&D expenses climbed 10.2% to $22.6M; company plans to develop ABS-201 internally while evaluating partnership options for future pipeline programs.
Last Updated: 12-08-2026, 02:52 am
Read Full Transcript

Earnings

Latest Release
11-08-2026
EPS / Forecast
-0.21 / -0.19
Revenue / Forecast
300K / 1.01M
EPS Revisions
Last 90 days

ABSI Income Statement

Compare ABSI to Peers and Sector

Metrics to compare
ABSI
Peers
Sector
Relationship
P/E Ratio
−13.0x−3.5x−0.4x
PEG Ratio
−0.86−0.040.00
Price/Book
6.4x2.3x2.6x
Price / LTM Sales
1,009.2x89.2x3.1x
Upside (Analyst Target)
52.5%159.5%47.9%
Fair Value Upside
Unlock4.5%6.3%Unlock

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
63.92M37.73%586.81M
Other Institutional Investors
81.90M48.35%751.87M
Public Companies & Retail Investors
23.57M13.92%216.41M
Total
169.4M100.00%1.56B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC13.31%2,25,50,9972,07,018
ARK Investment Management LLC8.10%1,37,26,1691,26,006

FAQ

What Is the Absci (ABSI) Share Price Today?

The Absci share price today is 9.180.

What is the current Absci (ABSI) share price and day range?

As of 17-08-2026, the Absci share price is 9.180, with a previous close of 9.180. The share price has ranged from 8.830 to 9.435 today, while the 52-week range spans from 2.240 to 12.055.

What Is the Absci Market Cap?

As of today, Absci market cap is 1.580B.

What Is the Absci (ABSI) Share Price Target?

The average 12-month share price target for Absci is 13.889, with a high estimate of 17 and a low estimate of 10. 9 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +51.30% Upside potential.

What Is Absci's Earnings Per Share (TTM)?

The Absci EPS (TTM) is -0.800.

When Is the Next Absci Earnings Date?

Absci will release its next earnings report on 17-11-2026.

From a Technical Analysis Perspective, Is ABSI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Absci Trade On?

Absci is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Absci?

The stock symbol for Absci is "ABSI."

How Many Times Has Absci Stock Split?

Absci has split 0 times.

How Many Employees Does Absci Have?

Absci has 140 employees.

What Is the ABSI Premarket Price?

ABSI's last pre-market stock price is 9.200. The pre-market share volume is 31,060.000, and the stock has changed by 0.020, or 0.220%.

What Is the ABSI After Hours Price?

ABSI's last after hours stock price is 9.100, the stock has changed by -0.080, or -0.870%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.